Terns Pharmaceuticals (TERN)
Track in portfolio
Price chart
Description
Company and Business Model
Terns Pharmaceuticals (TERN) is a biotechnology company focused on developing innovative therapies for liver diseases and other serious conditions. Its core products include TERN-101 and TERN-201, which target nonalcoholic steatohepatitis (NASH) and other metabolic disorders. The company primarily generates revenue through research and development partnerships and potential future product sales. Terns is positioned within the healthcare sector, emphasizing its commitment to addressing unmet medical needs.
Investment Profile
The investment profile of Terns Pharmaceuticals is more aligned with growth investors, given its focus on developing novel therapies and the potential for significant future revenue from product commercialization. The company currently does not offer dividends, and its financial performance indicates a focus on long-term value creation rather than immediate returns. Investors should consider the inherent risks associated with biotechnology investments and the company's developmental stage.
Fundamental metrics (experimental) Updated: 2026-09-06
- EPS (TTM) — earnings per share for the last 12 months, $
- -1.03
- EPS surprise
- 13.3%
- 20d volatility
- 0.0%
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-08 | Hold | Sell | Weak fundamentals with uncertain market conditions. |
| 2026-08-22 | Sell | Hold | Limited revenue, high risk; cautious approach advised. |
| 2026-08-12 | Hold | Sell | Weak fundamentals and uncertain market conditions persist. |
| 2026-05-08 | — | Hold | Strong momentum, but fundamental weaknesses persist. |
| 2026-05-08 | Hold | Hold | Компания демонстрирует значительный рост за последние 120 дней, что указывает на позитивные ожидания инвесторов. Однако отрицательный EPS и высокая волатильность требуют осторожности. |
| 2026-03-26 | — | Hold | Компания демонстрирует впечатляющий рост за последние 120 дней, что свидетельствует о высоком интересе инвесторов. Однако высокая волатильность и отсутствие данных по EPS и выручке требуют осторожности. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-03-27 | Mizuho Securities | Rating Downgraded | — → 53 | 52.92 |
| 2026-02-09 | Leerink Partners | Update | — → 58 | 37.73 |
| 2025-12-10 | Jefferies | Target Raised | — → 70 | 44.8269 |
| 2025-12-09 | Oppenheimer | Target Raised | 28 → 58 | 42.215 |
| 2025-12-09 | BMO Capital | Target Raised | 35 → 54 | 40.23 |
| 2025-12-09 | Truist Financial | Target Raised | 35 → 56 | 40.23 |
| 2025-12-09 | Mizuho Securities | Target Raised | 33 → 54 | 40.23 |
| 2025-12-09 | H.C. Wainwright | Target Raised | 20 → 60 | 40.23 |
| 2025-12-09 | Barclays | Target Raised | 36 → 56 | 40.23 |
| 2025-11-28 | Mizuho Securities | Update | — → 33 | 28.75 |
News Page 1 of 1
Nothing yet